U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. For Industry
  3. Medical products for rare diseases and conditions
  4. Pediatric Device Consortia Grants Program
  1. Medical products for rare diseases and conditions

Pediatric Device Consortia Grants Program

Pediatric medical device development faces unique challenges as children often differ from adults in size, growth, development, body chemistry, and disease propensity. Due in part to these issues, only a small number of medical devices approved are labeled for pediatric use. 

To address this health inequity, FDA funds the Pediatric Device Consortia (PDC) grants program to advance pediatric medical device development. These nonprofit consortia provide a platform of experienced regulatory, business planning, and device development services such as intellectual property advising, prototyping, engineering, laboratory testing, and grant- writing, to foster advancement of medical devices for pediatric patients. In addition to key advising services, the consortia also provide critical funding to innovators to directly advance these projects.  

The Food and Drug Omnibus Reform Act of 2022 reauthorized the PDC for fiscal years 2023 through 2027.

Funded Pediatric Device Consortia

In FY 2023, FDA funded a range of consortia to support pediatric medical device development. These awards include commitments to improving clinical trial infrastructure, advancing diversity and health equity as well as real-world evidence projects:

See the FY 2023 request for applications and Pediatric Device Consortia Grants Awarded for more information.

Additional resources

 



Back to Top